Catalysis is, often, the preferred approach to access chiral molecules in enantioenriched form both in academia and in industry; nowadays, organocatalysis is recognised as the third pillar in asymmetric catalysis, along with bio- and metalcatalysis. Despite enormous advancements in academic research, there is a common belief that organocatalysis is not developed enough to be applicable in industry. In this review, we describe a selection of industrial routes and their RandD process for the manufacture of active pharmaceutical ingredients, highlighting how asymmetric organocatalysis brings added value to an industrial process. The thorough study of the steps, driven by economic stimuli, developed and improved chemistry that was, otherwise, believed to not be applicable in an industrial setting. The knowledge discussed in the reviewed papers will be an invaluable resource for the whole research community.
File in questo prodotto:
Non ci sono file associati a questo prodotto.